FDA Approves Lyrfigtu, Third FGFR2 Drug for Bile Duct Cancer

LyrfigtuWhat to know

30-second read

For Oncology · Gastroenterology · Ophthalmology

Who

Adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a documented FGFR2 fusion or rearrangement, no prior FGFR inhibitor.

What’s new

Lirafugratinib (Lyrfigtu), a highly selective, irreversible, covalent FGFR2 inhibitor — the third such drug approved for this indication, not the first.

Evidence

REFOCUS, single-arm, n=116: 46% objective response, 96.5% disease control, median duration of response 11.8 months, median OS 22.8 months.

Big advantage

Higher reported response rate than either prior FGFR2 drug’s own trial, plus a selectivity profile designed to spare FGFR1/FGFR4 — though no head-to-head trial exists.

Key consideration

Retinal detachment in 31% (grade 3 in 1.8%) needs baseline and periodic eye exams; hyperphosphatemia in ~21% needs phosphate monitoring from day one.

Availability

Approved 23 September 2026. No U.S. list price or launch date announced by Elevar as of this writing.

Practice impactConsider for selected patients

A genuine third option for FGFR2-altered cholangiocarcinoma after progression on chemotherapy, with the class’s best-reported response rate to date — but cross-trial comparisons are soft, and the ophthalmologic monitoring burden is real, not optional.

Read the full physician analysis

Full analysis · 11 min readFDA approval notice, 23 Sep 2026 · Elevar Therapeutics release · REFOCUS data (J Clin Oncol 2026;44)

The FDA approved lirafugratinib (Lyrfigtu, Elevar Therapeutics) on 23 September 2026 for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma carrying an FGFR2 fusion or other rearrangement. It is an oral, once-daily, highly selective FGFR2 inhibitor with Breakthrough Therapy and Orphan Drug designations, and it is the third currently marketed drug in its class for this exact indication — not, as some early coverage implied, the first.

A crowded class, not an empty one

FGFR2 fusions and rearrangements drive an estimated 10–16% of intrahepatic cholangiocarcinomas, and targeting them has been an active drug class since 2020. Pemigatinib (Pemazyre) was the first, approved that year on a 35.5% response rate. Infigratinib (Truseltiq) followed in May 2021 on a 23.1% response rate, but Helsinn and BridgeBio voluntarily withdrew it from the U.S. market in May 2024 after enrollment problems sank the confirmatory trial required by its accelerated approval — a reminder that this entire class still carries confirmatory-trial obligations, not settled ones. Futibatinib (Lytgobi), approved in September 2022, brought a 35.8% response rate and a different mechanism: irreversible, covalent binding across all four FGFR receptors (FGFR1–4), designed for durability against resistance mutations that can blunt the earlier, reversible drugs. Lyrfigtu is therefore entering a field with two active predecessors, each already answering a version of the same question its own approval now answers again: does a new FGFR2 drug work after the others stop.

What lirafugratinib does differently

Lirafugratinib is also an irreversible, covalent inhibitor — it binds Cys491 in the FGFR2 kinase domain permanently rather than competing reversibly for the ATP pocket — but where futibatinib covalently inhibits all four FGFR receptors, lirafugratinib was engineered for FGFR2 selectivity specifically: roughly 250-fold selective over FGFR1 and 5,000-fold over FGFR4 in preclinical testing. The rationale, as lead REFOCUS investigator Lipika Goyal, MD (Stanford Cancer Institute) has described it, is that durable, sustained inhibition from covalent binding helps overcome resistance mutations that emerge with earlier-generation inhibitors, while sparing FGFR1 activity that is not the tumor’s driver — and that FGFR1 inhibition is itself implicated in the phosphate-metabolism disruption (hyperphosphatemia) that is a class-wide side effect. Whether tighter selectivity actually translates into less hyperphosphatemia in practice is not something this trial was designed to prove against a comparator; it is the mechanistic argument Elevar and REFOCUS investigators are making, not an independently confirmed clinical advantage.

Three FGFR2 inhibitors, one withdrawn

	Lyrfigtu (lirafugratinib)	Lytgobi (futibatinib)	Pemazyre (pemigatinib)
U.S. status	Approved 23 Sep 2026	Approved Sep 2022; marketed	Approved 2020; marketed
FGFR target	FGFR2-selective (irreversible, covalent)	Pan-FGFR1–4 (irreversible, covalent)	Pan-FGFR1–3 (reversible)
Pivotal trial design	REFOCUS, single-arm, n=116, FGFR-inhibitor-naive	FOENIX-CCA2, single-arm, n=103	FIGHT-202, single-arm, n=107 (FGFR2 fusion cohort)
Objective response rate	46% (95% CI 36–55)	35.8%	35.5%
Median duration of response	11.8 months	9.7 months	7.5 months
Named companion diagnostic	None identified in approval materials reviewed	FoundationOne CDx	FoundationOne CDx

Figures for Lytgobi and Pemazyre are each drug’s own labeled pivotal-trial results, not a head-to-head comparison against Lyrfigtu — cross-trial response-rate comparisons in different patient populations and periods are informative, not conclusive. A fourth drug, Truseltiq (infigratinib), was withdrawn from the U.S. market in May 2024 and is omitted as a current option.

The evidence behind the number

REFOCUS (NCT04526106) was a multicenter, open-label, single-arm trial. The 116 patients supporting this approval had unresectable or metastatic cholangiocarcinoma with a documented FGFR2 fusion or rearrangement, had received prior chemotherapy or chemoimmunotherapy, and had never been exposed to an FGFR inhibitor. Objective response rate was 46% (95% CI 36–55), disease control rate 96.5% (95% CI 91.3–99.0), median duration of response 11.8 months (95% CI 7.5–13.0), median progression-free survival 11.3 months (95% CI 9.2–14.8) and median overall survival 22.8 months (95% CI 18.1–27.2). The data were presented at the 2026 ASCO Gastrointestinal Cancers Symposium and published as a conference abstract (J Clin Oncol 2026;44(suppl 2):476); this reporting did not identify a full peer-reviewed journal publication of REFOCUS as of the approval date. As with every drug in this class, there is no randomized comparator: the trial measured lirafugratinib against itself, not against futibatinib, pemigatinib or chemotherapy, so the numerically higher response rate in the table above should be read as encouraging, not as proof of superiority.

The monitoring burden this approval adds

The recommended dose is 70 mg orally once daily until disease progression or unacceptable toxicity. The label’s warnings and precautions cover ocular toxicity, hyperphosphatemia and soft-tissue mineralization, and embryo-fetal toxicity. In the pooled safety population of 385 patients who received lirafugratinib across the development program, retinal pigment epithelial detachment occurred in 31% (grade 3 in 1.8%) — a rate that makes baseline and periodic ophthalmologic examination a practical requirement, not a formality, and one that puts an ophthalmologist into the care team for most patients on this drug. Hyperphosphatemia occurred in roughly 21% of patients, with a median onset around 15 days, requiring serum phosphate monitoring from treatment initiation. This reporting could not independently confirm whether FDA characterized this as an accelerated or a full approval; the evidence base — response rate and duration of response in a single-arm trial — is the kind of evidence that has come with a post-marketing confirmatory-trial obligation for every other drug in this class, including the one that was withdrawn when that obligation could not be met.

Availability, testing and access

Lyrfigtu is approved but Elevar has not published a U.S. list price or a specific launch date in its own communications as of this writing; this reporting found a single non-English financial-press reference to a fourth-quarter 2026 target that could not be independently corroborated, so treat any launch timing as unconfirmed until Elevar states it directly. Reimbursement, as a self-administered oral oncology drug, will run through the pharmacy benefit rather than a procedure code — the practice’s exposure is prior-authorization time, not billing, and payer policies have not yet been established for a drug approved one week before this story. FGFR2 fusion or rearrangement testing is required for eligibility, tested as it was in REFOCUS: locally or centrally, typically via a tumor genomic-profiling panel. No FDA-named companion diagnostic for Lyrfigtu specifically turned up in the approval materials this story reviewed, in contrast to Pemazyre and Truseltiq, which each name FoundationOne CDx in their own labels — confirm your lab’s panel is validated for FGFR2 fusion detection rather than assuming it qualifies.

What changes for the treating oncologist

• Sequencing. A patient who progresses on one FGFR2 inhibitor has not necessarily exhausted the class — but REFOCUS enrolled FGFR-inhibitor-naive patients only, so there is no trial evidence for using Lyrfigtu after futibatinib or pemigatinib have already failed. Resistance-mutation testing at progression, where available, is more informative than assuming cross-class efficacy.
• Build the ophthalmology relationship before starting, not after a finding. A 31% rate of retinal pigment epithelial detachment means most patients need a baseline exam and a monitoring schedule in place from day one.
• Phosphate monitoring starts immediately. Median onset of hyperphosphatemia was about 15 days — check it before the first follow-up visit, not at it.
• Confirm the FGFR2 test result is recent and the panel is adequate. No named companion diagnostic means the burden of confirming test adequacy falls more on the ordering physician than it does with Pemazyre or Truseltiq.
• Expect a coverage conversation, not a coverage answer. Nothing about pricing or payer policy is settled a week after approval.

The honest read is that Lyrfigtu is a real, evidence-supported addition to a small class of drugs for a rare, historically hard-to-treat cancer — and that its arrival is notable mainly for what it says about the class as a whole: three targeted drugs now compete for the same narrow population, one already failed commercially, and none has been tested against the others. For a patient in front of an oncologist today, that is a reason for cautious optimism about having options, not a reason to treat this as a breakthrough into unmet need.

How the FGFR2 class got here

1. Apr 2020

   Pemazyre approved

   First FGFR2 inhibitor for cholangiocarcinoma, on a 35.5% response rate in FIGHT-202.

2. May 2021

   Truseltiq approved

   Infigratinib cleared on a 23.1% response rate, with an accelerated-approval confirmatory-trial requirement attached.

3. Sep 2022

   Lytgobi approved

   Futibatinib brings pan-FGFR, irreversible covalent inhibition to the class.

4. May 2024

   Truseltiq withdrawn

   Sponsor pulls infigratinib after its confirmatory trial could not be completed as required.

5. Dec 2024

   Elevar in-licenses lirafugratinib

   Relay Therapeutics, which discovered and ran RLY-4008 through Phase 1/2, licenses global rights to Elevar/HLB.

6. 23 Sep 2026

   Lyrfigtu approved

   Third currently marketed FGFR2 inhibitor for this indication, on a 46% response rate.

7. Unannounced

   U.S. launch

   Price and launch date not yet published by Elevar.

Frequently asked questions

Is Lyrfigtu the first FGFR2 inhibitor for cholangiocarcinoma?

No. It is the third currently marketed FGFR2-targeted drug for FGFR2-altered cholangiocarcinoma, after pemigatinib (Pemazyre, 2020) and futibatinib (Lytgobi, 2022). A fourth, infigratinib (Truseltiq), was approved in 2021 but its sponsor withdrew it from the market in May 2024 after a confirmatory trial could not be completed — so the active field Lyrfigtu enters has two prior drugs, not three.

What monitoring does Lyrfigtu require that oncologists may not be used to?

Baseline and periodic ophthalmologic exams. In the trial supporting approval, retinal pigment epithelial detachment occurred in 31% of the 385 patients who received lirafugratinib across the development program, with grade 3 events in 1.8%. Hyperphosphatemia, a class effect of FGFR inhibition, occurred in about 21% of patients, with a median onset around 15 days — serum phosphate needs monitoring from the start of treatment.

Is FGFR2 fusion/rearrangement testing required, and is there a named companion diagnostic?

Patients must have a documented FGFR2 fusion or other rearrangement to qualify, tested locally or centrally, as in the REFOCUS trial. No FDA-named companion diagnostic for Lyrfigtu specifically was identified in the approval materials reviewed for this story — unlike Pemazyre and Truseltiq, which named FoundationOne CDx in their own approvals. Confirm coverage of whatever tumor-profiling panel your lab uses before assuming it satisfies the label.